These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26762799)

  • 1. Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.
    Liu CC; Zheng XJ; Ye XS
    ChemMedChem; 2016 Feb; 11(4):357-62. PubMed ID: 26762799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
    Sliepen K; Sanders RW
    Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.
    Williams WB; Wiehe K; Saunders KO; Haynes BF
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altering the Specificity of the Antibody Response to HIV gp120 with a Glycoconjugate Antigen.
    Liu CC; Zhai C; Zheng XJ; Ye XS
    ACS Chem Biol; 2016 Jun; 11(6):1702-9. PubMed ID: 27088577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
    Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
    Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.
    Wiehe K; Saunders KO; Stalls V; Cain DW; Venkatayogi S; Martin Beem JS; Berry M; Evangelous T; Henderson R; Hora B; Xia SM; Jiang C; Newman A; Bowman C; Lu X; Bryan ME; Bal J; Sanzone A; Chen H; Eaton A; Tomai MA; Fox CB; Tam YK; Barbosa C; Bonsignori M; Muramatsu H; Alam SM; Montefiori DC; Williams WB; Pardi N; Tian M; Weissman D; Alt FW; Acharya P; Haynes BF
    Cell Host Microbe; 2024 May; 32(5):693-709.e7. PubMed ID: 38670093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational antibody-based HIV-1 vaccine design: current approaches and future directions.
    Walker LM; Burton DR
    Curr Opin Immunol; 2010 Jun; 22(3):358-66. PubMed ID: 20299194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth.
    van Schooten J; van Gils MJ
    Retrovirology; 2018 Nov; 15(1):74. PubMed ID: 30477581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.
    Andrabi R; Voss JE; Liang CH; Briney B; McCoy LE; Wu CY; Wong CH; Poignard P; Burton DR
    Immunity; 2015 Nov; 43(5):959-73. PubMed ID: 26588781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
    Landais E; Moore PL
    Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
    McGuire AT
    Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
    Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint modulation enhances HIV-1 antibody induction.
    Bradley T; Kuraoka M; Yeh CH; Tian M; Chen H; Cain DW; Chen X; Cheng C; Ellebedy AH; Parks R; Barr M; Sutherland LL; Scearce RM; Bowman CM; Bouton-Verville H; Santra S; Wiehe K; Lewis MG; Ogbe A; Borrow P; Montefiori D; Bonsignori M; Anthony Moody M; Verkoczy L; Saunders KO; Ahmed R; Mascola JR; Kelsoe G; Alt FW; Haynes BF
    Nat Commun; 2020 Feb; 11(1):948. PubMed ID: 32075963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies and control of HIV: moves and countermoves.
    Hessell AJ; Haigwood NL
    Curr HIV/AIDS Rep; 2012 Mar; 9(1):64-72. PubMed ID: 22203469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HIV B Cell lines as candidate vaccine biosensors.
    Ota T; Doyle-Cooper C; Cooper AB; Huber M; Falkowska E; Doores KJ; Hangartner L; Le K; Sok D; Jardine J; Lifson J; Wu X; Mascola JR; Poignard P; Binley JM; Chakrabarti BK; Schief WR; Wyatt RT; Burton DR; Nemazee D
    J Immunol; 2012 Nov; 189(10):4816-24. PubMed ID: 23066156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.